Nicola A. Hanania, MD, MS - Enough: Targeting Eosinophilic Pathways With Biologics in Chronic Obstructive Pulmonary Disease

episode

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Stalingrad Of The Adriatic: The Sangro (Part 1) 52 min · 23 Sep 2026 · WW2 Pod: We Have Ways of Making You Talk

7PM ET 09/23/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

Richard’s Top 3 Music Videos Of All Time 35 min · 23 Sep 2026 · The Rest Is Entertainment

Would Sam & Pete Betray Each Other on Celebrity Traitors?! 37 min · 23 Sep 2026 · Staying Relevant

Mundane Truth | September 23, 2026 1h 52m · 23 Sep 2026 · The Steve Dangle Podcast

ON-AIR 🟢 - Poo-tane Gas 50 min · 23 Sep 2026 · The Morning Rumble

Report any issue

Source

Recorded12 Jan 2024

Publisherc.answersincme.com ↗

Handlerec:13096839

Show notes

Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in